Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12491 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Jie Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanjing Drum Tower Hospital, University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) includes simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and eventually cirrhosis and hepatocellular carcinoma (HCC). The diagnosis of NAFLD is based on the detection of excess fat disposition in the liver, which is the first step to trigger further evaluation of NAFLD, including necroinflammation and fibrosis. In this review, we discuss non‐invasive biomarkers and imaging tools that are currently and potentially available for different features (steatosis, necroinflammation and fibrosis) and disease severity assessment of NAFLD. In the past 2 decades, advances in non‐invasive tests of fibrosis have transformed the management of NAFLD. Blood and imaging biomarkers have already been evaluated in multiple studies for the diagnosis of fibrosis and cirrhosis. Among the various histological features of NAFLD, the degree of fibrosis has the strongest correlation with liver‐related morbidity and mortality. Non‐invasive tests of fibrosis have been shown to predict liver‐related outcomes, both in the general population and among patients with NAFLD. What is lacking, however, is good data to support the use of non‐invasive tests as monitoring and response biomarkers. With the conclusion of several large phase 3 studies in the next few years, the availability of paired liver biopsy, non‐invasive test and clinical outcome data will likely advance the field and shed light on new biomarkers and the way to use various non‐invasive tests in a longitudinal manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, University Medical School, Nanjing, China.
- Hepatology Unit, CHU Bordeaux, & BRIC, INSERM U1312, Bordeaux University, Bordeaux, France.
- Department of Medicine and Therapeutics, Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong, China.
- State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Victor de Lédinghen
Zitieren
APA
Li, J., Delamarre, A., Wong, V. W., & de Lédinghen, V. (2024). Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12491
Vancouver
Li J, Delamarre A, Wong VW, de Lédinghen V. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12491
BibTeX
@article{Li2024,
author = {Li, Jie and Delamarre, Adèle and Wong, Vincent Wai-Sun and de Lédinghen, Victor},
title = {Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12491}
}
EUVIMED